Guttikonda, Sudha R.
Sikkema, Lisa http://orcid.org/0000-0001-9686-6295
Tchieu, Jason http://orcid.org/0000-0002-9793-9836
Saurat, Nathalie
Walsh, Ryan M.
Harschnitz, Oliver http://orcid.org/0000-0001-6496-881X
Ciceri, Gabriele
Sneeboer, Marjolein
Mazutis, Linas
Setty, Manu http://orcid.org/0000-0002-0344-2627
Zumbo, Paul
Betel, Doron http://orcid.org/0000-0002-8006-7752
de Witte, Lot D.
Pe’er, Dana http://orcid.org/0000-0002-9259-8817
Studer, Lorenz http://orcid.org/0000-0003-0741-7987
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (1F30MH115616)
Tri-I Starr Stem Cell Scholar fellowship
Glenn/AFAR Postdoctoral Fellowship
NYSTEM fellowship
EMBO Fellowship
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (R21NS084334)
Article History
Received: 9 March 2020
Accepted: 24 December 2020
First Online: 8 February 2021
Competing interests
: L.S. holds equity and is a scientific co-founder and paid consultant of BlueRock Therapeutics. S.R.G. and L.S. are listed as inventors of a related patent application filed by the Memorial Sloan Kettering Cancer Center.